Monday, January 07, 2019 12:25:16 PM
but waiting could:
1. Help clear up any muddiness with respect to PFS.
2. Elucidate the response trajectory difference that may not start immediately.
3. Improve the HR in this trial as the estimates will be based on different trajectories. And much of the information will be actual not estimate
4. Provide information on the Duration of Response.
5. Provide information on any manufacturing improvements, whether it was collection of APCs or improvement in the maturation(specific to the hour) as reflected by the Direct Patent or both. It certainly looks like the later patients are doing much better.
6. Provide biomarkers, imaging or some other tell tale sign that can be used to show a patient is responding and can help predict the duration of responses in the future.(You know like a replacement for PFS as a surrogate for actual long term survival)
6. This could speed up future trials in other indications for L and Direct and confirm trial design and manufacturing design.
Those 100's of other treatments being developed would also have to wait a long time to get the data we will have. Perhaps adjusting the manufacturing and maturation of the APCs will keep this "Cutting Edge". Are you positive that some changes in the "L" trial will not impact direct? They found a way to make APCs more aggressive in 2013/14/15, do you think they wouldn't want to apply that knowledge and test it in "L"? I don't believe "L" trial was specific with how long maturation should be, so if they made a minor tweak from 24 hours to 16-18 hours(method b) it would still follow protocol. The results could prove to NWBO that the maturation window for Method B is working and the hypothesis from the observation in Direct would be confirmed at least internally.
I simply disagree, this is as cutting edge as it gets. What other trials do you know of that have broad applicability, long duration of response, a fat tail of survivors ~35%+ at 36mo+, with zero toxicity or QOL issues? As a patient the risk reward for taking this drug appears only to be economical. ...and I think "L" was improved from the early stages of the trial(while still being under protocol). Improved by a slight nuance in either the purity of collection or the specific time of maturation. Like cooking a frozen pizza, 5 minutes is too short, 25 minutes is too long but 13 minutes is just right. I am sure LP wishes she knew in 2008 what she knows now. It would have probably changed the dilution picture in 2012-15. More of it would have occurred at a higher stock price earlier on. In any case the wait is nearly over.
Too bad BMS bought Celgene, maybe they have more $ in coffers for M&A because they certainly "get it" when it comes to immuno-oncology.
https://www.immunooncologyhcp.bmsinformation.com/clinical-expectations/end-point-considerations
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM